Posted on Feb 25, 2022

THREAD Research CEO John Reites speaks on the state of remote and hybrid trials, and how COVID-19 has accelerated an already blossoming field.

The first technology-enabled remote clinical trial was launched nearly a decade ago, and that field – now generally referred to as "decentralized clinical trials" – has been advancing and gaining traction ever since. But, like so many other remote tools, it's been greatly accelerated by the COVID-19 pandemic.

On today's HIMSSCast, host Jonah Comstock and MobiHealthNews Managing Editor Laura Lovett welcome John Reites, CEO and cofounder of THREAD Research, to give us an update on where this new paradigm for clinical trials is today, and where it's headed.

Click here to listen to the podcast.

Talking points:

The effect of the pandemic on decentralized clinical trials.
Reconciling cultural differences between pharma and tech.
How vaccine trials are their own animal.
How decentralized trials can help improve clinical trial diversity.
The role of consumer wearables in clinical trials today.
Why clinical trial innovation must be global.
How physicians, researchers and patients are responding to new clinical trial models.
What everyone should know about decentralized clinical trials.

Like what you hear? Subscribe to the podcast on Apple Podcasts, Spotify or Google Play!

Original post: https://www.mobihealthnews.com/news/himsscast-decentralized-clinical-trials-2021-update

Photoillustration by Jonah Comstock. Photo courtesy John Reites

Refund Policy